Day One Biopharmaceuticals Inc (NASDAQ: DAWN) on Friday, soared 3.45% from the previous trading day, before settling in for the closing price of $6.95. Within the past 52 weeks, DAWN’s price has moved between $6.08 and $16.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -35.23%. With a float of $74.66 million, this company’s outstanding shares have now reached $101.35 million.
Considering the fact that the conglomerate employs 181 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 94.96%, operating margin of -118.31%, and the pretax margin is -38.25%.
Day One Biopharmaceuticals Inc (DAWN) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Day One Biopharmaceuticals Inc is 26.34%, while institutional ownership is 84.00%. The most recent insider transaction that took place on May 16 ’25, was worth 24,575. In this transaction Chief Commercial Officer of this company sold 3,927 shares at a rate of $6.26, taking the stock ownership to the 35,161 shares. Before that another transaction happened on May 16 ’25, when Company’s GENERAL COUNSEL sold 4,552 for $6.26, making the entire transaction worth $28,486. This insider now owns 47,136 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.23% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Day One Biopharmaceuticals Inc (DAWN) is currently performing well based on its current performance indicators. A quick ratio of 10.55 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.67, a number that is poised to hit -0.35 in the next quarter and is forecasted to reach -0.84 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
Compared to the last year’s volume of 1.25 million, its volume of 1.39 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 79.30%. Additionally, its Average True Range was 0.38.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 14.90%, which indicates a significant decrease from 88.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.43% in the past 14 days, which was lower than the 69.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.04, while its 200-day Moving Average is $11.36. Nevertheless, the first resistance level for the watch stands at $7.34 in the near term. At $7.49, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.65. If the price goes on to break the first support level at $7.03, it is likely to go to the next support level at $6.87. Now, if the price goes above the second support level, the third support stands at $6.72.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Key Stats
Market capitalization of the company is 728.80 million based on 101,362K outstanding shares. Right now, sales total 131,160 K and income totals -95,500 K. The company made 30,760 K in profit during its latest quarter, and -36,000 K in sales during its previous quarter.
